Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Peanut Allergy Pipeline Drugs Market Report Overview

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy – Drugs In Development, 2022, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 8, 3, 1, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 4 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).

– The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aimmune Therapeutics Inc
ALK-Abello AS
Allakos Inc
Allergy Therapeutics Plc
Angany Inc
Aravax Pty Ltd
AstraZeneca Plc
BioLingus AG
BlueWillow Biologics Inc
Cambridge Allergy Ltd
Cour Pharmaceuticals Development Co Inc
DBV Technologies SA
F. Hoffmann-La Roche Ltd
IgGenix Inc
Inimmune Corp
InnoUp Farma SL
Intrommune Therapeutics Inc
Mabylon AG
Moonlight Therapeutics Inc
Novartis AG
Phlaxis
Prota Therapeutics Pty Ltd
Regeneron Pharmaceuticals Inc
Sementis Ltd
Ukko Inc
Vedanta Biosciences Inc
Virtici LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peanut Allergy – Overview

Peanut Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peanut Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peanut Allergy – Companies Involved in Therapeutics Development

Peanut Allergy – Drug Profiles

Peanut Allergy – Dormant Projects

Peanut Allergy – Discontinued Products

Peanut Allergy – Product Development Milestones

Featured News & Press Releases

Jul 03, 2022: Aimmune Therapeutics to present new data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022

Jul 01, 2022: Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2022

Jun 27, 2022: ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy

Jun 22, 2022: Intrommune announces expanded scope of phase 1 OMEGA study in adults with peanut allergy

Jun 01, 2022: Intrommune Therapeutics names Nandini Murthy as head of regulatory

May 16, 2022: Prota Therapeutics achieves 51 percent peanut allergy remission rate, first company to validate significant quality of life improvements compared with standard care

May 11, 2022: Intrommune previews Phase II trial design for peanut allergy toothpaste

Apr 25, 2022: Allergy Therapeutics shares positive data on VLP Peanut at the 2022 WAO-BSACI Conference

Apr 06, 2022: INT301 continues to meet safety goals in phase 1 omega study in adults with peanut allergy while reaching phase 2 target maintenance dose

Mar 04, 2022: Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB

Mar 01, 2022: Allergy Therapeutics shares positive new data at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting

Feb 16, 2022: Aimmune Therapeutics announces publication of pooled safety analysis of PALFORZIA treatment for up to 2 years in the Journal of Allergy and Clinical Immunology

Feb 09, 2022: Prota Therapeutics achieves peanut allergy treatment milestone: groundbreaking clinical trial data demonstrates clinical remission of peanut allergy in paediatric patients

Feb 08, 2022: Intrommune reports positive update from ongoing phase 1 study in peanut allergy

Jan 26, 2022: Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Peanut Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Peanut Allergy – Pipeline by Aimmune Therapeutics Inc, 2022

Peanut Allergy – Pipeline by ALK-Abello AS, 2022

Peanut Allergy – Pipeline by Allakos Inc, 2022

Peanut Allergy – Pipeline by Allergy Therapeutics Plc, 2022

Peanut Allergy – Pipeline by Angany Inc, 2022

Peanut Allergy – Pipeline by Aravax Pty Ltd, 2022

Peanut Allergy – Pipeline by AstraZeneca Plc, 2022

Peanut Allergy – Pipeline by BioLingus AG, 2022

Peanut Allergy – Pipeline by BlueWillow Biologics Inc, 2022

Peanut Allergy – Pipeline by Cambridge Allergy Ltd, 2022

Peanut Allergy – Pipeline by Cour Pharmaceuticals Development Co Inc, 2022

Peanut Allergy – Pipeline by DBV Technologies SA, 2022

Peanut Allergy – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Peanut Allergy – Pipeline by IgGenix Inc, 2022

Peanut Allergy – Pipeline by Inimmune Corp, 2022

Peanut Allergy – Pipeline by InnoUp Farma SL, 2022

Peanut Allergy – Pipeline by Intrommune Therapeutics Inc, 2022

Peanut Allergy – Pipeline by Mabylon AG, 2022

Peanut Allergy – Pipeline by Moonlight Therapeutics Inc, 2022

Peanut Allergy – Pipeline by Novartis AG, 2022

Peanut Allergy – Pipeline by Phlaxis, 2022

Peanut Allergy – Pipeline by Prota Therapeutics Pty Ltd, 2022

Peanut Allergy – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Peanut Allergy – Pipeline by Sementis Ltd, 2022

Peanut Allergy – Pipeline by Ukko Inc, 2022

Peanut Allergy – Pipeline by Vedanta Biosciences Inc, 2022

Peanut Allergy – Pipeline by Virtici LLC, 2022

Peanut Allergy – Dormant Projects, 2022

Peanut Allergy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Peanut Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.